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The authors reviewed the passenger lymphocyte syndrome (PLS) that has appeared after transplantation. The deﬁnition,
mechanism, serological, clinical features, and treatment for PLS after solid organ transplantation, especially liver transplantation,
are described. The PLS refers to the clinical phenomenon of alloimmune hemolysis resulting from the adoptive transfer of
viable lymphocytes from donor during solid organ or hematopoietic stem cell transplant. Sometimes, it is very severe and
may cause “unexplained” hemolysis during the postoperative period. The authors reviewed literature about the PLS in liver
transplantation.
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1. INTRODUCTION
The passenger lymphocyte syndrome is due to the produc-
tion of antibodies by the donor B lymphocytes “passenger
lymphocytes” in a primary or secondary immune response
against the recipient’s red blood cell antigens [1].
PLS is mostly often seen in solid organ transplantation
with a minor ABO mismatch [1]. The factors that aﬀect the
severity of hemolysis including the quantity of transplanted
lymphoid tissue are: the level of red cells isoagglutinins in
the donor before transplant and the rapid rise in antibody
titer in the recipient after transplant [2]. It usually occurs
in 1–3 weeks posttransplant and resolves within 3 months
posttransplant, and is a self-limited process [3]. PLS usually
results from antibodies active against the ABO and Rh
systems.Rarely,itmayoccurduetonon-ABO/Rhantibodies,
particularly if the organdonor has been previously sensitized
to other red cell antigens by transfusion or pregnancy [4–
7]. It has been reported that PLS developed in two of four
patients who got organs for a same donor [5]. Hemolysis
due to PLS trends to be less common following solid organ
transplant [1, 3], and the relative frequency of PLS appears
to be related to the volume of transplanted lymphoid tissue.
It is more frequent in heart and lung transplants and less
in liver and kidney transplants. Only few anecdotal cases
are reported in the literature after liver transplantation [1–
5].
2. DEFINITION OF PLS
The appearance of unexpected antibodies of A and B
speciﬁcity in recipients of kidney allografts from ABO minor
mismatched donors was ﬁrst reported in the early 1980s.
Then, more than 100 cases involving liver, kidney, pancreas,
spleen, heart, lung, and heart-lung were published in 1991.
The source of the isohemagglutinins is viable donor B
lymphocytes passively transferred with the organ at the
time of transplantation. The phenomenon has been termed
the “passenger lymphocyte syndrome.” The donor origin
of the antibody has been conﬁrmed using immunoglobulin
allotyping [1]. During PLS, the donor memory B lym-
phocytes produce antibodies against recipient red blood
cells causing hemolysis [8]. A fascinating immunologic
phenomenon can occur in the setting of a minor ABO
mismatch. Viable lymphocytes contaminating the donor can
temporarily reside in the recipient, and if they are stimulated
shortly after transplant by recipient or transfused red cell
antigens, they can start producing antibodies during their
life. Leo et al. [9] reported that PLS with severe hemolytic
anemia was due to an anti-JKα on day 19 after allogeneic
peripheral blood progenitor cell transplantation.2 Clinical and Developmental Immunology
3. MECHANISM OF PLS 3:
ANTIBODY (AB), ANTIGEN (AG)
Three diﬀerent groups of ABO incompatibility can be distin-
guished in transplantation: minor, major, and bidirectional
ABO incompatibility. Major ABO-incompatible (e.g., A into
O) is characterized by the presence of preformed antidonor
A/B Ab directed against donor ABO Ag expressed on
transplanted cells. Recipients of minor ABO-incompatible
transplantation (e.g., O into A) express ABO Ag that are
not expressed in the donor and are at risk for graft-
versus-host (GvH) reactions such as delayed hemolysis of
recipient red blood cell (RBC) due to PLS. Although major
ABO-incompatible organs are not used routinely for trans-
plantation, minor ABO-incompatible organs are frequently
used to meet the demand for organs. Bidirectional ABO
incompatibility (e.g., A into B) represents a combination of
majorandminorABOincompatibilityandputstherecipient
at risk for both host-versus-graft and GvH [3].
Therefore, the PLS can be regarded as a type of graft-
versus-hostreaction.Mostcommonly,passengerlymphocyte
hemolysis is seen with a minor ABO mismatch, although
it can occur with other blood group system mismatches
[3–7]. Immunocompetent donor memory B lymphocytes
produce antibodies in a secondary immune response against
the recipient’s red cells. The massive red cells destruction
is thought to be complement-mediated [8]. Sokol et al. [3]
thought there were three diﬀerent posttransplant immune-
mediated hemolysis which are autoimmune hemolytic ane-
mia, PLS, and major blood mismatch. PLS is most common
within the ABO system when there is a minor mismatch
between the donor and the recipient, although it can occur
within other blood group system, such as Rh, Kidd, and
Lewis. Immunosuppression used posttransplantation has
an important etiologic role. Cyclosporine and tacrolimus
can permit rapid proliferation of spared lymphocyte B
cells, which produce antibodies. The antibodies typically
become evident at 5 to 17 days after transplant, and are
usually undetectable by 3 months. It is rarely fatal. However
during autoimmune hemolytic anemia, in allogeneic bone
marrow and/or peripheral blood progenitor cell transplants,
antibodies are produced by donor lymphocytes against
donor-produced red cells. While in solid organ transplants,
antibodies are produced by recipient lymphocytes against
recipient red cells. Then, during major blood group mis-
match, recipient produces antibodies against donor red cells.
4. PLS IN SOLID ORGAN TRANSPLANTATION
4.1. Livertransplantation
The incidence of biochemical PLS in liver transplantation
is 30%–40%. In fact, in almost all the cases (68–100%) the
antibodies are directed against Rh blood group antigens, and
only 30–40% of these antibodies led to immune hemolysis
[1, 4, 10–13].
Several reports have described the appearance of RBC
antibodiesinpatientsreceivinglivertransplantsfromimmu-
nized donors. In almost all of these cases, the antibodies
were directed against Rh blood group antigens, and only
a few of these antibodies led to moderate-severe immune
hemolysis(anti-D,13cases,anti-c,2cases,andanti-e,1case)
[4, 11, 12, 14].
PLS can develop abruptly and can vary from mild
to severe. The severity is mediated by the quantity of
transplanted lymphoid tissue, donor titers of isoagglutinins
and a rapid rise in antibody titer in the recipient after trans-
plantation [7]. Onset is usually 1–3 weeks posttransplant
and is a self-limited process, usually resolving by 3 months
posttransplant [13].
In particular, Triulzi et al. [14] reported that 56% (ﬁve
outofnine)oflivertransplantrecipientsdevelopedantibody,
and ﬁve had biochemical (low haptoglobin, high transam-
inases, and unconjugated bilirubin) evidence of hemolysis.
In Japan, it has been reported that two cases developed
hemolytic reaction due to graft-versus-host antibody in
livingdonorlivertransplantation[11].Shorttetal.[4]found
that severe hemolysis due to PLS in all three recipients of
organs from a single donor with multiple red cell alloanti-
bodies. The liver transplant recipient required augmentation
of immunosuppression to treat immune hemolysis due to
anti-B, -D, -C, and -Cellano (K). In addition, Grosskreutz
et al. [12] described HLA typing was critical diagnosis of the
recipient as Evans syndrome, and suggest that recipients of
solid organs from donors that are partially matched in the
direction of rejection may need to be closely monitored for
graft-versus-host disease.
5. OTHER SOLID ORGAN TRANSPLANTATION
Ramsey [15] reported that the frequency of PLS was highest,
at 70% in heart-lung transplant recipients, and 17% in
kidney transplant recipients. Salerno et al. [6]r e p o r t e da
study of seven minor ABO-incompatible lung transplant
recipients identiﬁed antibody and hemolysis in 57% (four
out of seven) and 29% (two out of seven), respectively.
It has been suggested that the amount of lymphoid tissue
transplanted with the organ accounts for these diﬀerences.
In addition, antibodies to red cell antigens outside the ABO
system have been reported in association with transplanted
kidney, pancreas-kidney, pancreas, liver, and heart-lung [1].
Seltsam et al. [5] found development of donor alloantibodies
in two recipients of separate organs (liver and pancreas-
kidney) from the same donor. Panaro et al. [7]r e p o r t e d
a severe hemolysis due to PLS in a living-related bowel
transplant recipient in an ABO-compatible donor-recipient
pair (O into A).
6. SEROLOGICAL FEATURES IN PLS
Donor-derived ABO antibody typically develops 7–14 days
after liver transplantation. At the same time, direct antiglob-
ulin test is always positive. The serum antibody is predom-
inantly IgG, but it may also be IgM. Passenger lymphocyte
derived antibodies are short-lived, persisting for about 2–
3 weeks in liver transplant recipients and 5 weeks in
kidney transplant recipients [1]. Using ﬂow cytometry and
nested polymerase chain reaction can diagnose the donor
lymphocyte microchimerism [5].Maxime Audet et al. 3
7. CLINICAL FEATURES IN PLS
PLS appears mostly in a variable proportion of ABO minor
mismatched organ transplant recipients. In liver transplant
recipients, from 68% [15] to 100% [14] with donor-derived
antibody develop hemolysis. Although the hemolysis is
usually mild and self-limited, substantial morbidity such as
acute renal failure, disseminated intravascular coagulation,
hypotension, and multiorgan failure, has been reported [1,
14–18].
8. TREATMENT FOR PLS
Today, there are no reliable factors can predict which
recipients of ABO minor mismatched organs will develop
passenger lymphocyte derived antibodies or PLS. Manage-
ment strategies for PLS are anecdotal, as described in case
reports and small series. Therapeutic interventions include
escalation of immunosuppression, immune modulation
(e.g., by IVIG) and speciﬁcally targeting B-lymphocytes
using monoclonal antibodies such as rituximab [7].
In most cases PLS can be treated only with transfusions.
Transfused red cells should be of organ donor ABO group
to replace susceptible red cells with cells that would not be
hemolyzed. Plasmapheresis or red cell exchange with donor-
type red cells may need to treat those who develop severe
hemolysis. Sometimes steroids is eﬀective to treat PLS. Anti-
CD20 monoclonal antibody (rituximab) is also eﬀective for
the severe patients.
There has been considerable interest in the past several
yearsin the use of the monoclonal antibodies widely used
in the treatmentof B-cell lymphoid neoplasms, namely
rituximab (Rituxan), and to a lesser extent alemtuzumab
(Campath-1H). Furthermore, the role of monoclonal anti-
bodies speciﬁcally rituximab, in the therapy of autoim-
munecytopenias has been validated recently. However, the
experience with the monoclonal antibodies for the PLS in
solid organ transplantation is very limited. In fact up-to-
date no experience was reported in case of PLS after LT.
It is likely thatas our experience with the drug evolves, it
will be used atan earlier point in therapy, before more toxic
immunosuppressives, rather than only in refractory cases
[19, 20].
Panaro et al. [7] reported a case of severe hemolysis due
to PLS occurred in a 4-year-old blood group A recipient of
living donor (blood group O) small-bowel transplantation.
The patient was treated successfully with plasmapheresis,
blood O transfusion, and rituximab. Sokol et al. [3]r evi e w e d
the treatment of hemolysis due to PLS posttransplant
including transfusion of compatible red cells and/or plasma
components with or without steroids, and maintenance of
adequate renal perfusion, plasma exchange and/or exchange
transfusion. Sometimes splenectomy should be considered.
9. CONCLUSION
Minor ABO mismatched organ transplants are often used
clinically. PLS is a common complication of this practice.
PLS can occur in 30%–40% of liver transplant recipients
including cadaveric and living donors. Today, no speciﬁc
treatment is available for the PLS. Therefore, PLS can be
treated with transfusion, plasmapheresis, red cell exchange,
and anti-CD20 monoclonal antibody.
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